Original Article
Treated for newly diagnosed Hodgkin's lymphoma with brentuximab vedotin: one case report and literature review
Ma Tao, Yuan Kaifeng, Xing Hongyun, Li Xiaoming, Wu Pengqiang, Chen Yan, Li Pan
Published 2017-12-01
Cite as Chin J Prim Med Pharm, 2017,24(23): 3598-3600. DOI: 10.3760/cma.j.issn.1008-6706.2017.23.020
Abstract
ObjectiveTo deepen the understanding of curative effect and adverse drug reaction of brentuximab vedotin in the treatment of Hodgkin's lymphoma.
MethodsOne case of newly diagnosed Hodgkin's lymphoma who treated with brentuximab vedotin was collected.The clinical features, laboratory examination, treatment procedure, prognosis were analyzed, and the relevant literature was reviewed.
ResultsThe patient was twenty years old, female, found the right neck masses for five days, diagnosed with Hodgkin's lymphoma, mixed cell type, stage IV group B. Chose the chemotherapy regimen BV+ GABVD for 4 courses, the PET-CT indicated CR, then used GABVD 4 courses, now in the stage of clinical observation and followed up.
ConclusionBV is a kind of antibody-drug conjugate which targeted on CD30 protein.The FDA approved for the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma.The common adverse reactions are granulocyte, peripheral neuropathy, fatigue, nausea and vomiting.BV can significantly improve the prognosis of CD30 positive Hodgkin's lymphoma, but need to pay attention to the prevention of adverse reactions.
Key words:
Lymphoma; Antigens, CD30; Brentuximab vedotin; Prognosis
Contributor Information
Ma Tao
Department of Hematology, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China
Yuan Kaifeng
Xing Hongyun
Li Xiaoming
Wu Pengqiang
Chen Yan
Li Pan
